Astrakhan

Researchers are conducting an observational multicenter cross-sectional study involving 5,000 adult patients in Russia with uncontrolled severe asthma SA who are receiving standard care treatments except biologics. The study aims to describe the characteristics of these patients across about 50 outpatient centers in 50 regions of Russia, addressing the lack of unified data on severe asthma epidemiology, complications, comorbidities, and treatment patterns in the country. Participants will have a single study visit where demographic and clinical data will be collected without any additional interventions or changes to their routine care. The study will gather information on treatment patterns, including the use of oral corticosteroids and various medication classes, and analyze clinical and demographic features such as age at diagnosis, gender distribution, body mass index, lifestyle factors, and presence of comorbidities. During the study, researchers will review medical records and follow-up data from the prior 52 weeks to assess treatment changes, exacerbations, healthcare resource use, and lung function parameters. No extra diagnostic or therapeutic procedures will be performed beyond standard practice. The study will run from June 2024 to June 2027, aiming to provide detailed epidemiological insights into uncontrolled severe asthma in the Russian adult population.

Researchers are studying uncontrolled asthma in adults across Russia to better understand its characteristics and treatment patterns. This large-scale observational registry will include 9,000 patients from 70 outpatient centers in about 50 regions, focusing on those not receiving biologic therapy. The study aims to describe demographic and clinical features, capture complications and comorbidities, and evaluate routine therapies used in real practice. The study has an ambispective design with two main visits. At the first visit, physicians will collect baseline data from the past 52 weeks using medical records and patient interviews. The second visit, conducted 12 weeks later, will gather follow-up information on treatment changes and clinical outcomes. A subgroup of 500 patients using fixed-dose combination budesonidesalbutamol will have an additional third visit 12 weeks after the second to collect further data. Participants will undergo routine clinical assessments during 2 to 3 visits following standard practice. Researchers will examine demographic and clinical data, blood and sputum eosinophil counts, total IgE levels, asthma control status, lung function tests, exacerbation rates, and healthcare resource use. Safety monitoring aligns with routine care, and the study does not involve any experimental treatments or procedures. Total participation spans approximately 24 weeks for those in the extended follow-up group.

Researchers are evaluating the efficacy and safety of treating chronic anal fissure, a painful rupture in the anal canal lasting over two months and resistant to non-surgical treatments. The study compares two treatment approaches botulinum toxin injections and lateral subcutaneous sphincterotomy surgery. The condition mainly affects younger and working-age adults and involves internal sphincter muscle spasm as a key factor. One treatment group receives complex therapy including surgical removal of the fissure without cutting the internal sphincter, followed by injections of Botulinum Toxin Type A directly into the internal anal sphincter at four points. The other group undergoes lateral subcutaneous sphincterotomy, where the internal sphincter muscle is partially cut using a scalpel under anesthesia. Both procedures are performed under spinal anesthesia in a surgical setting. Participants will be monitored for up to 60 days after treatment. Researchers will assess anal sphincter insufficiency, pain intensity at multiple time points, wound healing, sphincter muscle function, temporary disability, and recurrence of the fissure. The study aims to understand differences in treatment effects, including frequency and duration of post-operative incontinence, by comparing these two approaches for chronic anal fissure.

Researchers are collecting detailed information on patients with extreme hypertriglyceridemia, a condition where triglyceride levels are 10 mmolL or higher. This observational registry, conducted across multiple centers in Russia, aims to understand the clinical, demographic, and genetic features of these patients. The study also looks at current methods used for diagnosis and treatment in everyday medical practice to help guide future research and improve patient care. Patients included in the registry have confirmed extreme hypertriglyceridemia based on at least two separate blood tests. There are no treatments or procedures done as part of the study instead, it records patients clinical progress, lab results, lipid profiles, and any therapies being used as part of their regular care. Genetic testing results are also documented when available. Patients are followed up at least once a year or more often if needed based on their health. Participants continue their usual medical care with their doctors while researchers collect data such as mortality rates, major cardiovascular events, pancreatitis episodes, cholesterol levels, triglyceride levels, and genetic findings over an average of 20 years. Data collection is voluntary and confidential, with patients able to withdraw at any time without affecting their treatment. The study started in November 2025 and will continue through December 2045.

Researchers are investigating how other existing health conditions affect the risk of complications after abdominal surgery. This observational study aims to understand the frequency and types of additional diseases among surgical patients and identify key factors that predict postoperative problems. The goal is to help better assess and manage risks for patients undergoing planned abdominal operations. The study collects information about patients age, gender, physical status by the ASA scale, presence of various diseases such as heart, lung, kidney, neurological, and metabolic conditions, and treatments they receive. It also records details about the type and severity of surgery, anesthesia methods, and uses various assessment scales related to cognition, respiratory and cardiovascular risk, liver and kidney function. Data is gathered before surgery and patients are monitored until hospital discharge. Participants provide informed consent and their data is entered into a secure database. Researchers evaluate factors influencing complications within 7 days after surgery, as well as mortality within 30 days. Statistical analysis includes regression models to identify independent risk predictors. The study involves multiple centers and follows patients throughout the hospital stay, aiming to improve understanding of postoperative risks and guide preventive strategies.

This research aims to study rickettsioses by identifying the genetic types of bacteria causing these infections in patients from regions of Russia. It is an observational, non-interventional study involving patients who have been diagnosed with or are suspected to have tick-borne rickettsioses. The study collects and analyzes biological samples to better understand the relationship between the bacterial types, patient symptoms, and disease progress. During the study, there is no change or influence on the patients routine treatment or diagnostic process, which follows standard medical care. Residual biological samples such as blood, plasma, buffy coat, serum, or swabs from skin lesions are collected and analyzed for rickettsial genotypes. Medical history, disease progression, symptoms, and treatments are recorded in individual case report forms. The study has received ethical approval and participants provide informed consent. Participants will have their medical history and symptoms documented, along with collection of leftover diagnostic samples. Researchers will perform genetic identification of the rickettsia species within approximately four weeks. The study monitors clinical patterns linked to specific bacterial types while maintaining regular care for patients. Participation involves data and sample collection only, with no experimental treatment. The study is expected to continue until the end of 2026.